Devaiah Prashasthi, Handjiev Sava, George Jacob
Year 3 Medical Student School of Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY.
Clinical Biochemistry Registrar Department of Clinical Biochemistry, Ninewells Hospital & Medical School, Dundee, DD1 9SY.
Br J Cardiol. 2023 Nov 29;30(4):44. doi: 10.5837/bjc.2023.044. eCollection 2023.
Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.
尽管他汀类药物和其他降血脂疗法被广泛用于治疗高胆固醇血症，但心血管（CV）死亡率和发病率仍然很高。前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂阿利西尤单抗和依洛尤单抗已在英国被批准用于治疗家族性高胆固醇血症和高心血管风险的患者。我们回顾了苏格兰一个大型健康委员会中被处方使用这些药物的患者记录，以确定它们在常规临床护理中的实际疗效和耐受性。
